Bullfrog AI Holdings, Inc. (NASDAQ:BFRG - Get Free Report) CEO Vininder Singh sold 7,245 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $1.61, for a total value of $11,664.45. Following the sale, the chief executive officer now directly owns 2,385,201 shares in the company, valued at approximately $3,840,173.61. This trade represents a 0.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Vininder Singh also recently made the following trade(s):
- On Thursday, April 3rd, Vininder Singh sold 27,958 shares of Bullfrog AI stock. The stock was sold at an average price of $1.44, for a total transaction of $40,259.52.
Bullfrog AI Trading Down 14.0 %
Shares of NASDAQ:BFRG opened at $1.41 on Friday. The firm has a 50 day moving average of $2.31 and a 200-day moving average of $2.35. Bullfrog AI Holdings, Inc. has a 12 month low of $1.35 and a 12 month high of $4.84. The stock has a market capitalization of $13.28 million, a PE ratio of -1.66 and a beta of 0.33.
Bullfrog AI (NASDAQ:BFRG - Get Free Report) last released its earnings results on Friday, March 14th. The company reported ($0.18) earnings per share for the quarter.
Institutional Trading of Bullfrog AI
Several institutional investors and hedge funds have recently modified their holdings of BFRG. Raymond James Financial Inc. acquired a new position in Bullfrog AI during the fourth quarter worth about $30,000. Geode Capital Management LLC boosted its stake in shares of Bullfrog AI by 31.0% in the 4th quarter. Geode Capital Management LLC now owns 47,093 shares of the company's stock valued at $94,000 after purchasing an additional 11,140 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new stake in shares of Bullfrog AI during the 4th quarter valued at approximately $41,000. 0.96% of the stock is currently owned by institutional investors.
Bullfrog AI Company Profile
(
Get Free Report)
Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
